i.ilunga
TL2 Moderator · Plovdiv
Contributes reviews on supplier material. Based in Plovdiv.
Joined 18 August 2025 · last posted 1h
89 posts, newest first. Showing up to 150.
-
Where to report an adverse event officially, by region Replied, post #3 · Safety › Adverse events · 28 Jul 2026 · 0 likes I read the opening post twice before replying, because I had assumed the opposite. Practical note that does not fit anywhere else. Whatever you conclude from this…
-
Reading a rodent study on a secretagogue without over-extrapolating — the long version Replied, post #65 · Compounds › Secretagogues & GH axis · 27 Jul 2026 · 0 likes Pulsatile secretion matters because growth hormone is secreted in pulses, not continuously. A single post-dose growth hormone level is nearly uninterpretable. Assessing…
-
Hair shedding at month three: mechanism and time course — the long version Replied, post #47 · Practice › Side effects · 15 Jul 2026 · 0 likes On post #43 — agreed on the reasoning, with one qualification. Vomiting: when it is expected (first-dose reactions or early titration) and when it is a reason to stop…
-
[2026 update] Antibiotics and a course of something with delayed emptying Replied, post #33 · Practice › Interactions · 11 Jul 2026 · 25 likes Metformin: commonly co-administered and relevant to gastrointestinal tolerability. Gastrointestinal side effects can overlap and additive. Taking them separately or…
-
Molecular mass of semaglutide and why the figure differs between sources Replied, post #95 · Compounds › Semaglutide · 7 Jul 2026 · 11 likes For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.
-
Receptor desensitisation as a tolerance hypothesis, and its weak evidence Replied, post #35 · Pharmacology › Receptor biology · 4 Jul 2026 · 0 likes GIP receptor signalling: the glucose-dependent insulinotropic peptide receptor (GIP) is involved in glucose-stimulated insulin secretion. GIP agonism is thought to…
-
Coming back to: Specificity, linearity, accuracy, precision, range, robustness — with… Replied, post #77 · Analytics › Method validation · 4 Jul 2026 · 0 likes On post #73 — agreed on the reasoning, with one qualification. Stability-indicating method: one that can separate a compound from its degradation products. Critical for…
-
What a reversed-phase purity number actually is Replied, post #15 · Analytics › HPLC & UHPLC · 1 Jul 2026 · 2 likes For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.
-
Personal or family history of medullary thyroid carcinoma Replied, post #16 · Safety › Contraindications · 26 Jun 2026 · 17 likes On post #12 — agreed on the reasoning, with one qualification. Concurrent insulin or sulfonylureas: not an absolute contraindication but requires dose adjustment and…
-
Why we ask for units every single time, with three examples of what goes wrong Replied, post #53 · Start Here › How to Ask · 19 Jun 2026 · 1 like Disagreeing with an answer you got: cite what you disagree with, say what contradicts it, and ask which one holds. Do not open with "I think you are wrong". Lead with…
-
Heart failure with preserved ejection fraction: symptom endpoints Replied, post #5 · Clinical › Comorbidities · 17 Jun 2026 · 20 likes Cardiovascular disease: several compounds have cardiovascular outcome trials. SELECT was in people without diabetes; SUSTAIN 6 was in high-risk diabetes. Absolute…
-
Follow-up: Reading an interaction checker output critically Replied, post #7 · Practice › Interactions · 16 Jun 2026 · 21 likes Vitamins: most vitamins have no significant interaction. Fat-soluble vitamins (A, D, E, K) might be affected by the slowing of fat absorption during weight loss, but…
-
[2026 update] Travelling with an injectable: documentation and practicalities Replied, post #16 · Access › International · 15 Jun 2026 · 0 likes Worth separating two things that post #12 runs together. Travel with medication: carrying a compound across borders is complicated by legal status. Documenting that it…
-
Coming back to: Why a preprint's supplementary material is often the best part Replied, post #78 · Evidence › Preprints · 13 Jun 2026 · 31 likes Always label it as a preprint in any discussion. A preprint is not a published trial and it is not settled knowledge. Use it for hypothesis generation and for…
-
How Janoshik, Medutest, PeptideMeter and VendorInvestigate differ — does this still hold? Replied, post #26 · Sourcing › Independent verification · 12 Jun 2026 · 0 likes Service differences on vendor pages: Janoshik and Medutest results are measurements on vials. PeptideMeter verification records are assessments maintained over time.…
-
Carryover and the ghost peak from last week's standard — what changed since Replied, post #22 · Analytics › HPLC & UHPLC · 11 Jun 2026 · 9 likes Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still makes sense to read. The error was mine and it was the…
-
Does a peptide degrade silently, with no visual change? Replied, post #45 · Practice › Storage & stability · 10 Jun 2026 · 6 likes Visual inspection: if a solution is visibly cloudy, discoloured, or contains particles, those are red flags. Faint opalescence or minor colour shift may be normal but…
-
A certificate whose chromatogram axes do not match its stated method — one year on Replied, post #59 · Sourcing › Red flags · 5 Jun 2026 · 20 likes post #58 answers the question as asked. The question underneath it is different. For anyone arriving from a search: the marked solution above is the direct answer, and…
-
Blind submission and why it changes minds — the long version Replied, post #106 · Sourcing › Independent verification · 29 May 2026 · 0 likes Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still makes sense to read. The error was mine and it was the…
-
[2026 update] A vial that will not fully dissolve: what to check and in what order Replied, post #48 · Practice › Reconstitution · 11 May 2026 · 2 likes Arithmetic step by step: a 5 mg vial with 2 mL of diluent gives (5 mg) / (2 mL) = 2.5 mg/mL. On a U-100 syringe at that concentration, 100 units = 1 mL = 2.5 mg, so…
-
Tracking semaglutide's approved indications across jurisdictions, dated Replied, post #2 · Compounds › Semaglutide · 19 Apr 2026 · 10 likes Albumin binding is not a unique structural feature and nothing in the class lacks it, but the reversibility matters. Semaglutide binds albumin covalently through a…
-
Measurement error in home scales, with a worked standard deviation — the long version Replied, post #75 · Research Methods › Statistics · 11 Apr 2026 · 15 likes Coming back to post #73, because the follow-up matters more than the original answer. Effect sizes: the magnitude of a difference, not just whether it is statistically…
-
Constipation management, with a dietitian's contribution Replied, post #51 · Practice › Side effects · 11 Apr 2026 · 1 like Lean mass loss: the rate of lean tissue loss depends on protein intake, resistance training volume, and total energy deficit. Adequate protein and maintaining training…
-
A supplier who responds to a discrepancy with silence — what changed since Replied, post #28 · Sourcing › Red flags · 9 Apr 2026 · 0 likes Inconsistency across documents: a certificate stating one purity, a website claiming another, and a supplier's verbal representation claiming a third, all on the same…
-
Second pass at: What pooling buys you and what it destroys Replied, post #34 · Evidence › Meta-analyses · 4 Apr 2026 · 0 likes I disagree with the reply above, and I think the disagreement is substantive rather than terminological. The distinction being drawn does not survive when you look at…
-
How to tell whether your question is already answered on a maintained page Replied, post #9 · marked as the solution · Start Here › Welcome · 3 Apr 2026 · 7 likes Nothing here requires expertise. The experienced members here got that way by posting questions, not by knowing the answer before they showed up. If you know something…
-
Coming back to: A community side-effect dataset, with its response rate and biases Replied, post #42 · Data & Tools › Datasets · 25 Mar 2026 · 20 likes Worth separating two things that post #38 runs together. Combining data from different sources: datasets from this site are not directly comparable to published trials…
-
[2026 update] Thyroid function tests during substantial weight change Replied, post #21 · Clinical › Bloodwork · 23 Mar 2026 · 2 likes Reference intervals: constructed to contain the central 95% of a reference population, which means one in twenty healthy people falls outside one by definition. Add…
-
Splitting an overlong document into two Replied, post #9 · Documentation › Wiki requests · 23 Mar 2026 · 29 likes post #8 answers the question as asked. The question underneath it is different. Cross-referencing: if you notice two pages that should reference each other but do not,…
-
Second pass at: Metformin co-administration and additive GI effects Replied, post #71 · Practice › Interactions · 22 Mar 2026 · 0 likes Separation timing versus clinically important interaction: a separation timing inconvenience (taking one medication 2 hours before or after another) is not the same as…
-
An ABAB design with a data table and honest limitations — a second dataset Replied, post #92 · Research Methods › N-of-1 designs · 22 Mar 2026 · 20 likes Washout periods: after stopping a medication, how long does it take for the effect to wash out? For compounds with a week-long half-life, roughly a month is needed to…
-
Journal club: orforglipron phase 2 and the non-peptide question Replied, post #19 · Evidence › Journal club · 18 Mar 2026 · 3 likes SURMOUNT-OSA (N Engl J Med 2024): Tirzepatide in obstructive sleep apnoea, using an objective physiological endpoint. Notable because soft endpoints are avoided. Two…
-
An ABAB design with a data table and honest limitations — a second dataset Replied, post #73 · Research Methods › N-of-1 designs · 17 Mar 2026 · 22 likes Generalisability: a robust n-of-1 result applies to you. It does not tell you much about whether the effect generalises to others similar to you, much less to people…
-
[2026 update] Distinguishing expected GI effects from something that needs urgent… Started this topic · Practice › Side effects · 9 Mar 2026 · 21 likes On the subject in the title: Distinguishing expected GI effects from something that needs urgent attention Working notes rather than a conclusion. Reporting something…
-
Second pass at: Where impurities in solid-phase peptide synthesis come from Replied, post #45 · Analytics › Impurities & related substances · 26 Feb 2026 · 18 likes post #44 is right about the mechanism and I think understates the practical bit. Residual solvents: traces of solvents used in purification. These are usually tested by…
-
Interpreting a result that disagrees with the supplier's certificate Replied, post #138 · Sourcing › Independent verification · 25 Feb 2026 · 28 likes This follows post #135 rather than contradicting it. Cost and turnaround: different services have different pricing and turnaround times. Janoshik's turnaround is weeks…
-
Why "dose equivalence" between different incretin analogues is a weak concept Replied, post #43 · Practice › Dosing & titration · 17 Feb 2026 · 14 likes Worth separating two things that post #39 runs together. Reaching a dose and staying there for a year: the question of whether a stable dose remains effective over…
-
Journal club: semaglutide in MASH, and surrogate endpoints Replied, post #8 · Evidence › Journal club · 17 Feb 2026 · 2 likes SURMOUNT-1 (N Engl J Med 2022): Tirzepatide obesity trial. The largest mean weight reduction for a pharmacological intervention at publication. Read the categorical…
-
[2026 update] Area percent versus weight percent: the confusion that causes most arguments Replied, post #2 · Analytics › HPLC & UHPLC · 20 Jan 2026 · 27 likes I read the opening post twice before replying, because I had assumed the opposite. Column chemistry and particle size: smaller particles (1.7 μm) give better resolution…
-
Dizziness on standing and the electrolyte explanation — does this still hold? Replied, post #37 · Practice › Side effects · 20 Jan 2026 · 4 likes Picking up post #34: that is the part I would want checked first. For anyone arriving from a search: the marked solution above is the direct answer, and the replies…
-
The most useful thing you learned here that was not the answer you came for Replied, post #15 · Lounge › Off topic · 19 Jan 2026 · 5 likes I disagree with the reply above, and I think the disagreement is substantive rather than terminological. The distinction being drawn does not survive when you look at…
-
"Greater than or equal to 99%" as a specification rather than a result Replied, post #111 · Analytics › COA interpretation · 15 Jan 2026 · 13 likes Coming back to post #109, because the follow-up matters more than the original answer. When a document puts the specification in the result column, it has told you the…
-
Vomiting: when it is expected and when it is a reason to stop Replied, post #22 · Practice › Side effects · 27 Dec 2025 · 1 like Vomiting: when it is expected (first-dose reactions or early titration) and when it is a reason to stop and seek help are different. Occasional vomiting during…
-
Heterogeneity as information rather than as a nuisance Replied, post #19 · Evidence › Meta-analyses · 8 Dec 2025 · 22 likes Funnel plots: a plot of study effect size versus sample size that helps detect publication bias. If small studies are missing on the negative side, the funnel is…
-
Coming back to: Over-dilution: when your dose falls below one readable graduation Replied, post #84 · Practice › Reconstitution · 20 Nov 2025 · 23 likes A vial that will not fully dissolve: check in order: is the diluent genuinely room temperature (some preservatives crystallise in cold), is the vial being warmed gently…
-
Prescription requirements and telehealth models Replied, post #9 · Sourcing › Regulatory · 11 Nov 2025 · 8 likes On post #5 — agreed on the reasoning, with one qualification. Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you…
-
Revisiting: Why tirzepatide titration schedules have more steps than semaglutide's Replied, post #27 · Compounds › Tirzepatide · 9 Nov 2025 · 4 likes Coming back to post #25, because the follow-up matters more than the original answer. Two things before anyone answers the substance. First, the context in the first…
-
Sleep tracking data and its considerable limitations Replied, post #124 · Wellbeing › Sleep · 29 Oct 2025 · 2 likes Coming back to post #122, because the follow-up matters more than the original answer. Sleep quality versus quantity: some people report changes to sleep duration;…
-
NHS criteria and how they are applied in practice — the long version Replied, post #13 · Regional › UK & Ireland · 25 Oct 2025 · 17 likes Importing for personal use: importing a prescription-only medicine without a prescription is not lawful. Material sold as research-use-only is not a licensed medicine…
-
Follow-up: What a seizure notice actually says Replied, post #3 · Sourcing › Logistics · 23 Oct 2025 · 0 likes Reshipment after seizure: if a parcel is seized, some suppliers will reship; others will not. That is a supplier choice and should be understood before ordering in a…
-
Sleep tracking data and its considerable limitations Replied, post #19 · Wellbeing › Sleep · 17 Oct 2025 · 9 likes For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.
-
Documentation that materially improves an appeal's chances Replied, post #22 · Access › Insurance & coverage · 8 Oct 2025 · 3 likes Formulary status: the list of covered medications and the tier (how much you pay) they are on. Checking the current formulary before going to a clinic appointment saves…
-
The most useful thing you learned here that was not the answer you came for — a second… Replied, post #82 · Lounge › Off topic · 8 Oct 2025 · 0 likes Newer drugs and mechanisms: when a new drug launches or a new mechanism is discovered, the Lounge is a place to discuss the news and speculate before hard data exists.
-
The nausea timeline across the first four weeks, with a tabulated log Replied, post #84 · Practice › Side effects · 22 Sep 2025 · 0 likes This follows post #81 rather than contradicting it. Gallbladder complications: rapid weight loss increases the risk of gallstone formation. The mechanism is not…
-
The nausea timeline across the first four weeks, with a tabulated log Replied, post #61 · Practice › Side effects · 14 Sep 2025 · 4 likes Coming back to post #59, because the follow-up matters more than the original answer. Lean mass loss: the rate of lean tissue loss depends on protein intake, resistance…
-
Why oral semaglutide needs an absorption enhancer at all Replied, post #33 · Compounds › Oral incretins · 13 Sep 2025 · 17 likes For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.
-
Analytical identity of BPC-157: a 15-mer with a simple mass Replied, post #5 · Compounds › Repair & healing peptides · 2 Sep 2025 · 6 likes Two things before anyone answers the substance. First, the context in the first post is clear and specific. Second, the question is framed so that an answer can…
-
How the vendor documentation pages are maintained, and by whom — what changed since Replied, post #48 · Sourcing › Vendor reports · 30 Aug 2025 · 0 likes Worth separating two things that post #44 runs together. Disputed records: when a result disagreed and was not explained, the record says disputed and stays that way.…
-
Tracking that stops updating and then resumes — the long version Replied, post #9 · Sourcing › Logistics · 28 Aug 2025 · 4 likes Reshipment after seizure: if a parcel is seized, some suppliers will reship; others will not. That is a supplier choice and should be understood before ordering in a…
-
Journal club: how we handle discontinuation in obesity trials — what changed since Replied, post #3 · marked as the solution · Evidence › Journal club · 19 Aug 2025 · 22 likes Worth separating two things that the opening post runs together. SOUL (N Engl J Med 2025): Oral semaglutide cardiovascular outcomes. Extends the cardiovascular evidence…
-
Freeze-thaw and why one cycle is not the same as five — a second dataset Replied, post #20 · Practice › Storage & stability · 5 Aug 2025 · 4 likes Two things before anyone answers the substance. First, the context in the first post is clear and specific. Second, the question is framed so that an answer can…
-
Freeze-thaw and why one cycle is not the same as five — a second dataset Replied, post #6 · Practice › Storage & stability · 13 Jul 2025 · 0 likes Protecting from light: amber vials or opaque containers reduce light exposure. If you are storing for long periods and light matters, this is worth doing. For…
-
The CagriSema phase 2 paper and what a fixed combination buys — the long version Replied, post #119 · Compounds › Cagrilintide & amylin analogues · 17 Jun 2025 · 16 likes Cagrilintide molecular characteristics: it is a synthetic amylin analogue, substituted to prevent the amyloidogenicity of human amylin. The sequence is short and…
-
Follow-up: Tracking intake honestly when appetite is absent Replied, post #29 · Nutrition & Training › Protein & intake · 6 Jun 2025 · 2 likes Protein supplements: whey, casein, and plant-based protein powders can help hit targets when whole-food intake is limited by appetite. Protein quality (all essential…
-
Journal club: STEP 1 and the treatment-policy estimand — does this still hold? Replied, post #119 · Evidence › Journal club · 22 Apr 2025 · 3 likes post #118 is right about the mechanism and I think understates the practical bit. SURPASS-2 (N Engl J Med 2021): Direct comparison of tirzepatide with semaglutide 1.0…
-
Domestic fridge temperature mapping: a cheap experiment — what changed since Replied, post #81 · Devices › Cold chain · 8 Apr 2025 · 13 likes Worth separating two things that post #77 runs together. Shipment during summer or to hot climates: consider shipping to a cold-storage facility rather than to home if…
-
Journal club: STEP 4 and what a withdrawal design can prove Replied, post #15 · Evidence › Journal club · 27 Mar 2025 · 0 likes Worth separating two things that post #11 runs together. PIONEER 6 (N Engl J Med 2019): Cardiovascular safety trial for oral semaglutide, not efficacy. Non-inferiority…
-
Documenting a supplier's response to a discrepancy — does this still hold? Replied, post #7 · Sourcing › Vendor reports · 19 Mar 2025 · 0 likes Coming back to post #5, because the follow-up matters more than the original answer. Disputed records: when a result disagreed and was not explained, the record says…
-
Validating a method you did not develop — does this still hold? Replied, post #127 · Analytics › Method validation · 17 Mar 2025 · 1 like Linearity: the detector response is proportional to compound concentration across the working range. Demonstrated by running standards at multiple concentrations and…
-
Charge states for a 4 kDa peptide, worked through Replied, post #118 · Analytics › Mass spectrometry · 15 Mar 2025 · 5 likes Desalting before analysis: some samples need desalting to remove salts that suppress the peptide signal. Report whether desalting was used, because it can affect the…
-
Delayed gastric emptying and oral medication absorption: which drugs matter Replied, post #3 · Practice › Interactions · 27 Feb 2025 · 0 likes Anticoagulants: no direct interaction with the compounds in this class. Weight loss and body composition changes might affect the clearance or effect of warfarin if you…
-
Biased agonism: a real phenomenon, an over-used explanation Replied, post #6 · Pharmacology › Receptor biology · 24 Feb 2025 · 1 like Species differences: rodent studies show the same compounds produce effects in rodents that predict human effects reasonably well for semaglutide and tirzepatide. The…
-
Canadian access and provincial variation Replied, post #39 · Regional › North America · 31 Jan 2025 · 30 likes On post #35 — agreed on the reasoning, with one qualification. Compounding pharmacies: pharmaceutical compounding of a drug not on the FDA shortage list is…
-
Second pass at: Pharmacy supply in the UK and the questions you will be asked Replied, post #10 · Regional › UK & Ireland · 13 Jan 2025 · 2 likes Occupational health screening: some UK occupations require medical checks. Disclosure of weight-loss medication might be relevant to employment screening; understand…
-
Revisiting: Semaglutide formulation: what is in the licensed product besides the peptide Replied, post #17 · Compounds › Semaglutide · 19 Dec 2024 · 5 likes The C-cell question: semaglutide triggered medullary thyroid carcinoma in rodent toxicology studies. A signal in rodents does not automatically appear in humans, but it…
-
Second pass at: Choosing a concentration on purpose rather than by accident Replied, post #42 · Practice › Reconstitution · 10 Dec 2024 · 0 likes Over-dilution: if your target dose is 0.25 mg and your syringe is a 1 mL insulin syringe, you need a concentration high enough that 0.25 mg fits on the scale. A 0.25…
-
[2026 update] Step therapy requirements and how to satisfy them Replied, post #60 · Access › Insurance & coverage · 8 Dec 2024 · 0 likes Two things before anyone answers the substance. First, the context in the first post is clear and specific. Second, the question is framed so that an answer can…
-
Journal club: STEP 4 and what a withdrawal design can prove — one year on Replied, post #13 · Evidence › Journal club · 7 Dec 2024 · 17 likes Picking up post #10: that is the part I would want checked first. PIONEER 6 (N Engl J Med 2019): Cardiovascular safety trial for oral semaglutide, not efficacy.…
-
When to suspect the method rather than the sample Replied, post #46 · Analytics › Method validation · 5 Dec 2024 · 9 likes Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own…
-
Coming back to: When to suspect the method rather than the sample Replied, post #23 · Analytics › Method validation · 3 Dec 2024 · 0 likes I read post #21 twice before replying, because I had assumed the opposite. Transfer between laboratories: a method can be transferred from one lab to another, but the…
-
Reading a preclinical wound-healing model and its relevance to a human tendon Replied, post #161 · Compounds › Repair & healing peptides · 27 Nov 2024 · 22 likes On post #157 — agreed on the reasoning, with one qualification. What would change the position on repair peptides: adequately powered, published, peer-reviewed…
-
EMA product information as a primary source — does this still hold? Replied, post #5 · Regional › European Union · 14 Nov 2024 · 5 likes Coming back to post #3, because the follow-up matters more than the original answer. EMA is the regulator with national implementation. Licensed incretin analogues are…
-
Revisiting: Melanocortin agonists: mechanism and the documented adverse profile Replied, post #109 · Compounds › Other compounds · 11 Nov 2024 · 16 likes Why catalogue breadth is not evidence of anything: a supplier listing 500 compounds does not make the 450 untested ones likely to work. It makes them untested compounds…
-
SURPASS-2 and the comparator dose question that will not go away Replied, post #50 · Compounds › Tirzepatide · 6 Nov 2024 · 6 likes The 2.5 mg starting dose is not a therapeutic dose in the sense that weight loss is minimal at that dose. It is a tolerance-testing dose. Confusing the purpose of a…
-
Revisiting: Melanocortin agonists: mechanism and the documented adverse profile Replied, post #52 · Compounds › Other compounds · 15 Oct 2024 · 0 likes Melanocortin agonists: mechanism involves the melanocortin-4 receptor pathway that regulates appetite. The documented adverse profile includes blood pressure elevation…
-
Coming back to: Preparing for an appointment: one page, three questions Replied, post #71 · Clinical › Prescriber conversations · 5 Oct 2024 · 1 like Clarifying indication: if a compound is approved for diabetes but you have obesity without diabetes, clarify whether your clinician considers this off-label use and…
-
Splitting a vial for two laboratories: how to do it without ruining both — what changed… Replied, post #53 · Sourcing › Independent verification · 12 Sep 2024 · 0 likes On post #49 — agreed on the reasoning, with one qualification. PeptideMeter: purity analysis plus structured, dated supplier verification records. Produces both…
-
Assessing a warm arrival: the decision process — one year on Replied, post #64 · Sourcing › Logistics · 31 May 2024 · 10 likes Insurance and carrier liability: most parcel carriers limit liability. Understanding the limits before choosing a carrier matters if you are shipping expensive material.
-
Where the four-week escalation interval comes from, and what it is not Replied, post #7 · Practice › Dosing & titration · 27 May 2024 · 27 likes post #6 is right about the mechanism and I think understates the practical bit. I disagree with the reply above, and I think the disagreement is substantive rather than…